Construction Administration Associate Director Evangelia Ieronymaki’s research advances a structural model that may improve ...

The issue is that six years ago, Prime appeared to sign away its rights to create AATD treatments to another company it has long collaborated with, Beam Therapeutics.

Beam Therapeutics Inc. BEAM announced positive initial safety and efficacy data from a phase I/II study, which is evaluating its pipeline candidate, BEAM-302, for treating patients with alpha-1 ...

(RTTNews) - Beam Therapeutics Inc. (BEAM) Monday reported positive initial data from its Phase 1/2 study of BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD). AATD is an ...

She has 15+ years of experience as a financial writer and technical analyst. Companies use the equity method of accounting to report their investments in other entities where they have significant ...